Soaring Nausea and Vomiting in Transgender Women After Facial Feminization
For transgender women, facial feminization surgery represents more than a medical procedure—it's a vital step toward aligning their physical appearance with their true gender identity.
Explore the ResearchRecent research has uncovered a disturbing trend—transgender women undergoing these complex procedures experience postoperative nausea and vomiting (PONV) at rates dramatically higher than other surgical populations.
This isn't merely about temporary discomfort; PONV can prolong hospital stays, delay recovery, and transform what should be an empowering experience into a traumatic ordeal. The discovery of this disparity has sparked urgent questions about the unique physiological factors at play and how anesthesia protocols must evolve to better serve this growing patient population.
Facial feminization surgery encompasses a suite of specialized procedures designed to modify facial features to create a more feminine appearance. These surgical interventions are far more than cosmetic enhancements—they're medically necessary treatments that can significantly alleviate gender dysphoria and dramatically improve quality of life for transgender women 7 .
Softening the browline to create a more feminine forehead shape.
Refining the nose to achieve more delicate, feminine proportions.
Reducing angularity to create softer, more rounded facial contours.
Reducing the Adam's apple for a more feminine neck appearance.
These procedures are often performed in combination, resulting in lengthy operative times that frequently exceed those of comparable cosmetic procedures like rhinoplasty 1 . The complexity and duration of these operations may contribute to the heightened risk of postoperative complications including nausea and vomiting.
In 2023, a groundbreaking study conducted at Boston Medical Center revealed the astonishing disparity in PONV rates between transgender women and other surgical populations. The researchers undertook a comprehensive retrospective review of 282 transgender women who had undergone FFS between 2014 and 2020, comparing their outcomes to 375 cisgender patients (123 men and 252 women) who had undergone rhinoplasty procedures during the same period 1 3 .
The investigation employed rigorous scientific methods to ensure meaningful results:
Researchers conducted detailed retrospective chart reviews of all patients who underwent FFS at the institution during the study period 1 .
Comprehensive data was gathered including patient demographics, hormone use history, comorbidities, and previous history of PONV 1 .
The study defined PONV as any episode of nausea and/or vomiting occurring before discharge from the medical facility 1 .
A cisgender cohort undergoing rhinoplasty served as controls, allowing researchers to distinguish procedure-specific factors from patient-specific factors 1 .
Multivariate logistic regression analyses were performed to control for confounding variables and isolate the true effect of gender identity on PONV risk 1 .
Transgender women undergoing FFS experienced PONV 1
Cisgender rhinoplasty patients experienced PONV 1
| Patient Population | Number of Patients | PONV Incidence | Percentage |
|---|---|---|---|
| Transgender women undergoing FFS | 282 | 104 | 37% 1 |
| Cisgender rhinoplasty patients | 375 | 41 | 11% 1 |
The statistical analysis confirmed that transgender women experienced significantly higher PONV rates than cisgender patients even after controlling for other known risk factors. Perhaps most surprisingly, the study found that discontinuation of hormone therapy before surgery—a common preoperative protocol—showed no significant influence on PONV incidence 1 3 .
The dramatically elevated PONV rates in transgender women undergoing FFS cannot be explained by conventional risk models alone. Several intersecting factors likely contribute to this clinical phenomenon.
Research has previously established that higher estrogen levels correlate with increased PONV risk, as evidenced by higher rates in women during their periovulatory phase when estrogen peaks 1 . Transgender women typically undergo feminizing hormone therapy that includes estrogen, which may create a physiological environment primed for nausea and vomiting responses.
FFS procedures are notably lengthy and complex, often combining multiple facial procedures in a single operation. The study confirmed that FFS procedures had significantly longer duration than the rhinoplasty procedures performed on control patients 1 . Longer anesthesia exposure is a well-established risk factor for PONV.
The study revealed that transgender women presented with significantly higher rates of depression and anxiety compared to both cisgender men and women in the control group 1 . Psychological stress is known to influence the autonomic nervous system, which plays a crucial role in nausea and vomiting pathways 5 .
Despite the concerning findings, recent research offers hope for dramatically reducing PONV in this vulnerable population.
A 2022 study demonstrated that implementing a comprehensive, standardized anesthetic and antiemetic regimen throughout all surgical phases can yield remarkable improvements 6 .
PONV rate with old regimen (as-needed antiemetics) 6
PONV rate with new standardized regimen 6
The new protocol was associated with a six-fold reduction in PONV after adjusting for age, BMI, and smoking status, with a calculated odds ratio of 0.15 compared to the old regimen 6 . This demonstrates that targeted intervention can effectively address the problem.
Successful protocols typically incorporate multi-modal approaches that target different pathways in the nausea and vomiting reflex:
Scopolamine patches, oral phenergan, and steroids to preemptively calm nausea pathways .
Use of propofol infusions when possible, minimization of volatile anesthetics and opioids, and adequate hydration 6 .
Combining medications that target different receptor systems (5-HT3 antagonists, NK1 antagonists, dopamine antagonists, corticosteroids) 5 .
| Medication Category | Example Agents | Primary Mechanism of Action |
|---|---|---|
| 5-HT3 Receptor Antagonists | Ondansetron, Granisetron | Blocks serotonin receptors in the gut and brainstem 5 |
| NK1 Receptor Antagonists | Aprepitant (Emend) | Inhibits substance P activity in the brain's nausea centers 5 |
| Anticholinergics | Scopolamine patches | Blocks acetylcholine receptors responsible for vestibular nausea |
| Corticosteroids | Dexamethasone | Reduces inflammatory responses that trigger nausea pathways |
| Antihistamines | Promethazine (Phenergan) | Blocks histamine receptors in the vomiting center |
| Dopamine Antagonists | Droperidol, Metoclopramide | Inhibits dopamine receptors in the chemoreceptor trigger zone 5 |
The disproportionately high incidence of postoperative nausea and vomiting in transgender women undergoing facial feminization surgery represents both a challenge and an opportunity—a chance to transform surgical care for a vulnerable population that has historically faced significant healthcare disparities.
As surgical teams become more knowledgeable about these unique risks, they can implement the evidence-based strategies that have proven effective in dramatically reducing PONV. The goal is not merely to prevent an unpleasant symptom, but to ensure that gender-affirming surgeries—so crucial to psychological well-being and quality of life—are not overshadowed by preventable postoperative suffering 7 .
Through continued research, specialized anesthetic protocols, and heightened clinical awareness, the medical community can honor its commitment to providing truly comprehensive, compassionate, and effective care for transgender patients. The path forward is clear: by recognizing and addressing the unique physiological challenges these patients face, we can make transformational surgery a more comfortable and positive experience for all.
References will be listed here in the final version.